Experimental or clinical studies show promising therapeutic results by targeting IL-1β signaling for a broad spectrum of disorders including cardiovascular disease and cancer treatment-associated life-threatening cytokine release syndrome [85–88]. This evidence concerns the gene IL1B and cardiovascular disorder.